Related Experiment Video
Updated: Apr 6, 2026

qKAT: Quantitative Semi-automated Typing of Killer-cell Immunoglobulin-like Receptor Genes
Published on: March 6, 2019
Association between KIR gene polymorphisms and rheumatoid arthritis susceptibility: A meta-analysis
Xiaona Li1, Qing Xia1, Dazhi Fan1
1Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, 81 Meishan Road, Hefei, Anhui 230032, China.
Objectives:
The results of studies on association between KIR (killer cell immunoglobulin-like receptors) polymorphisms and susceptibility to RA (rheumatoid arthritis) are inconsistent. To comprehensively evaluate the effect of KIR polymorphisms on the risk of RA, a meta-analysis was carried out.
Methods:
The Web of Science, PubMed, the Chinese Biomedical Database (CBM) and Chinese National Knowledge Infrastructure (CNKI) databases were systematically searched to select studies on the association between KIR polymorphisms and RA. The odds ratio (OR) with 95% confidence interval (95%CI) was obtained.
Results:
Nine qualified case-control studies were included in this meta-analysis. The results showed there were two positive associations of 2DL1, 2DS1 (OR2DL1=2.20, 95%CI=1.20-4.01, Praw=0.01, PFDR=0.03; OR2DS1=1.84, 95%CI=1.19-2.85, Praw=0.006, PFDR=0.018) and one negative association of 2DL3 (OR2DL3=0.42, 95%CI=0.22-0.79, Praw=0.006, PFDR=0.018) with susceptibility to RA in East Asians, but not in Caucasians.
Conclusion:
The current meta-analysis provides evidence that 2DL3 might be a potential protective factor and 2DL1, 2DS1 might be risk factors for RA in East Asians but not in Caucasians.
More Related Videos
Related Concept Videos
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
The JAK-STAT Signaling Pathway
Rheumatic Heart Disease I: Introduction
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

